FULC Insider Trading
Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $59,071.84
Fulcrum Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Fulcrum Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Fulcrum Therapeutics Share Price & Price History
Current Price: $4.00
Price Change: ▲ Price Increase of +0.04 (1.01%)
As of 01/21/2025 05:00 PM ET
Fulcrum Therapeutics Insider Trading History
Fulcrum Therapeutics Institutional Trading History
Data available starting January 2016
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More on Fulcrum Therapeutics
Volume
867,973 shs
Average Volume
628,414 shs
Market Capitalization
$215.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.06
Who are the company insiders with the largest holdings of Fulcrum Therapeutics?
Who are the major institutional investors of Fulcrum Therapeutics?
Which major investors are selling Fulcrum Therapeutics stock?
Within the previous quarter, FULC stock was sold by these institutional investors:
- SG Americas Securities LLC
In the previous year, company insiders that have sold Fulcrum Therapeutics company stock include:
- Greg Tourangeau (Insider)
- Greg Tourangeau (VP)
Learn More investors selling Fulcrum Therapeutics stock.